$インヒビカセ セラピューティクス(IKT.US)$Inhibikase Therapeutics - Upon Completion of Double-Blinded Phase of 201 Trial, We Expect to Request an End of Phase 2 Meeting With FDA by End of 2024
Trytosaveabitスレ主taijahmed75:
Im guessing it because they said to shareholders Friday there is a big concern whether they will have enough money to continue
$インヒビカセ セラピューティクス(IKT.US)$Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension Benzinga· 3 mins ago
$インヒビカセ セラピューティクス(IKT.US)$Inhibikase Reports Preliminary Outcomes Of Pre-NDA Meeting With FDA On Pathway For Approval For IkT-001Pro In Blood And Gastrointestinal Cancers; Says Given Specific Guidance On Manufacturing Requirements Necessary To Complete NDA
1
1
報告
Trytosaveabitスレ主 :
We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval," said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. "Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission," noted Dr. Werner.
インヒビカセ セラピューティクスに関するコメント
Benzinga· 3 mins ago
読み込み中...
まだコメントはありません